NEPRO

Across TCGA pan-cancer cohorts, NEPRO mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of NEPRO’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where NEPRO mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types NEPRO is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, LSCC, and LUAD are the cancer types where NEPRO tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NEPRO mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	+0.474	<.001	11	view →
LSCC	Male	III,IV	+0.638	<.001	9	view →
LUAD	Male	III,IV	+0.463	<.001	9	view →
CCRCC	All	II,III,IV	+0.155	<.001	8	view →
COAD	All	All	+0.418	.001	5	view →
PDAC	All	IV	−0.373	.026	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

NEPRO–HNSC

Open the HNSC breakdown →